Bowel cancer screening in Australia: NBCSP, FOBT, and colonoscopy surveillance

Colorectal cancer (CRC) is the second-most common cause of cancer death in Australia, with approximately 15,000 new diagnoses and 5,000 deaths annually. Lifetime risk for the general population is around 1 in 13 (7.5%). The striking statistic is that most colorectal cancers arise from adenomatous polyps over a period of years to decades — making screening uniquely effective: detecting and removing polyps prevents cancer from developing, and detecting early-stage cancers dramatically improves survival (stage I: ~90% five-year survival; stage IV: ~13%).

The GP’s role in the National Bowel Cancer Screening Program (NBCSP) is central: promoting participation, addressing barriers, following up positive results with timely colonoscopy referral, and coordinating post-colonoscopy surveillance. Australia has made measurable progress on bowel cancer screening, but participation rates remain suboptimal — approximately 40 to 45% of eligible people complete the test, with Aboriginal and Torres Strait Islander Australians participating at rates around 40% compared with the national average.

A. Core clinical — the AU general-practice framework

The National Bowel Cancer Screening Program (NBCSP)

Who is eligible: All Australians aged 45 to 74 years — expanded from age 50 to 45 from 1 July 2024, following emerging evidence of rising early-onset colorectal cancer and adoption of the USPSTF 2021 recommendation extending screening to age 45. Eligible people receive a free immunochemical FOBT (iFOBT / FIT) kit mailed every two years.

How iFOBT works: The iFOBT uses antibodies to detect human haemoglobin in stool — it does not require dietary restrictions (unlike older guaiac FOBT). Two stool samples are collected and posted to the laboratory. Sensitivity per round: approximately 70% for colorectal cancer; specificity approximately 95%. The positive predictive value for a confirmed colorectal cancer is around 5%; for any significant neoplasia (cancer or adenoma) approximately 50%.

Result pathway:

• Negative → re-invitation in two years
• Positive → GP follow-up and referral for diagnostic colonoscopy — target within 30 days

The GP’s role in the NBCSP: Promote participation during consultations; address cultural, language, and practical barriers; provide the kit in-clinic for those who have not received or completed theirs; follow up patients whose positive results have not been actioned; coordinate post-colonoscopy surveillance intervals.

Symptomatic patients — bypass the FOBT entirely

A critical distinction: symptomatic patients need diagnostic colonoscopy directly — never a screening FOBT to triage symptoms. Using iFOBT in symptomatic patients is inappropriate and can provide false reassurance, leading to delayed diagnosis.

Red flags requiring direct colonoscopy referral per the RACGP Red Book:

• Rectal bleeding mixed with stool (dark blood, clots, blood inside the pan)
• Change in bowel habit persisting ≥6 weeks (constipation, looseness, alternating, or urgency)
• Iron deficiency anaemia in any man of any age, or any postmenopausal woman — mandatory colonoscopy plus upper GI endoscopy
• Unexplained weight loss
• Palpable abdominal or rectal mass
• Persistent abdominal pain without clear aetiology in an older patient
• Abnormal imaging suggesting colonic pathology

Fresh rectal bleeding on the toilet paper alone in a young person with no risk factors is lower risk but still warrants assessment; age above 50, family history, or change in stool character increases the threshold for direct investigation.

Family history risk stratification

The Cancer Council Australia Surveillance Colonoscopy Guidelines (2018) use a three-category framework that every GP should apply during health assessments and preventive care consultations:

Category 1 — average risk (no affected first-degree relatives, or one first-degree relative diagnosed at ≥55 years):

• Continue with NBCSP biennial iFOBT

Category 2 — moderately increased risk (one first-degree relative diagnosed under 55 years, OR two first-degree relatives at any age, OR one second-degree relative diagnosed under 55 years):

• Colonoscopy every five years starting at age 50, or ten years younger than the youngest affected relative — whichever comes first
• iFOBT between colonoscopies

Category 3 — high risk (multiple first-degree relatives, hereditary syndrome suspected):

• Specialist clinical genetics referral for formal assessment
• Intensive early surveillance starting in the 20s for Lynch syndrome; teenage years for FAP
• Genetic testing and cascade testing of family members

Colonoscopy surveillance intervals after polyp removal

Following the NHMRC and Cancer Council 2018 guidelines, the post-polypectomy surveillance interval is determined by baseline findings:

Findings	Surveillance interval
No polyps, or distal hyperplastic polyps under 10 mm	Return to NBCSP biennial iFOBT
Low-risk adenoma: 1–2 tubular adenomas under 10 mm, low-grade dysplasia	5 to 10 years
Intermediate-risk: 3–4 adenomas, OR ≥10 mm, OR villous/tubulovillous, OR high-grade dysplasia	3 years
High-risk: ≥5 adenomas, OR ≥20 mm	1 year
Serrated polyposis syndrome	1 year
Post-curative resection of CRC	1 year, then 3 years, then 5-yearly

B. Evidence appraisal — what works and what doesn’t

iFOBT reduces colorectal cancer mortality

The Cochrane meta-analysis (Hewitson et al.) on faecal occult blood testing for colorectal cancer — aggregating major RCTs — demonstrates 13 to 18% relative risk reduction in CRC mortality with biennial FOBT screening. The effect accumulates over multiple screening rounds; a single negative result is not sufficient reassurance. The iFOBT (FIT) performs better than older guaiac FOBT and does not require dietary restriction.

Polypectomy is highly effective at CRC prevention

The National Polyp Study demonstrated that colonoscopy with polypectomy reduces CRC incidence by 76 to 90% over 20 years compared with expected rates. This is the strongest cancer prevention intervention available. The quality of the endoscopist matters — adenoma detection rate (ADR) should be ≥25% in men and ≥15% in women; higher ADR correlates with lower interval cancer rates. When referring for colonoscopy, GPs can ask the endoscopy service about their ADR.

The 2024 age expansion to 45

The expansion from age 50 to 45 in the NBCSP from 1 July 2024 responds to evidence of a rising incidence of early-onset colorectal cancer in adults under 50, a trend seen in Australia and internationally. Young adults with rectal bleeding or change in bowel habit should not be dismissed — early-onset CRC has different molecular features and outcomes than sporadic older-onset disease.

Lynch syndrome — the most common hereditary CRC syndrome

Lynch syndrome (previously HNPCC) — caused by mutations in MMR genes (MLH1, MSH2, MSH6, PMS2, EPCAM) — carries a lifetime CRC risk of 50 to 80% and a mean age of diagnosis around 45 years. There is also significant risk of endometrial, ovarian, urothelial, and gastric cancers. Universal MMR/MSI testing of all newly diagnosed colorectal cancers is now recommended to identify Lynch syndrome patients and trigger cascade genetic testing of families — this is increasingly standard in Australian tertiary centres. Colonoscopy every one to two years from age 25 (or five years before the earliest affected family member) is the surveillance standard for confirmed Lynch syndrome mutation carriers.

C. Hereditary colorectal cancer syndromes

Three syndromes require specific management and early specialist referral:

Familial Adenomatous Polyposis (FAP) — APC gene mutation causing hundreds to thousands of colorectal adenomas by young adulthood. Without treatment, CRC is nearly inevitable by age 40. Management: annual sigmoidoscopy or colonoscopy from age 12, with prophylactic colectomy when polyp burden warrants. Refer to a Familial Cancer Centre.

Lynch syndrome / HNPCC — described above. Any person with a first-degree relative diagnosed with Lynch syndrome, or with a colorectal cancer showing MMR deficiency on tumour testing, should be referred for formal genetic assessment and counselling.

MAP (MUTYH-Associated Polyposis) — biallelic MUTYH mutation; autosomal recessive; 10 to 100 polyps; CRC risk significantly elevated. Identified through genetic testing, often in the context of unexplained multiple polyps.

D. Australian operations

MBS items relevant to general practice:

• Standard consultations: items 23, 36, 44
• ATSI Health Assessment: item 715 — opportunity to discuss NBCSP participation and address barriers; ATSI Australians have lower uptake and higher mortality
• 75+ Health Assessment: item 707 — screening review at every annual assessment
• Colonoscopy (specialist-billed): items 32084 / 32087 diagnostic colonoscopy; items 32090 / 32093 with polypectomy
• CT colonography: item 56505 — Medicare-funded for specific indications when colonoscopy is contraindicated; sensitivity ~95% for lesions ≥10 mm but lacks therapeutic capacity
• Pathology: iron studies items 66596 / 66599 — mandatory when iron deficiency anaemia is the presenting indication

NBCSP administration: The program mails kits to eligible people every two years. GPs can provide in-clinic kits for patients who have not received or completed theirs. The NBCSP notifies the patient’s nominated GP of positive results, though patients often present without this having occurred — always ask about screening status at preventive health consultations.

Specialist referral pathways: Gastroenterologist or colorectal surgeon for colonoscopy (positive iFOBT, symptomatic red flags, family history surveillance); clinical genetics or Familial Cancer Centre for suspected hereditary syndrome; multidisciplinary colorectal cancer team for confirmed CRC.

Australian support resources: Bowel Cancer Australia 1800 555 494; Cancer Council Australia 13 11 20; Lynch Syndrome Australia; state-based Familial Cancer Services.

E. Special populations

ATSI Australians — participation in the NBCSP is approximately 40% compared with the national average of around 45%. CRC mortality is higher in this population. Opportunistic kit provision during any consultation, support with completion, and partnership with Aboriginal Health Workers meaningfully improve uptake. The ATSI Health Assessment item 715 is a structured opportunity.

People with IBD — ulcerative colitis with pancolitis, or extensive Crohn’s colitis, carries elevated CRC risk increasing with extent and duration. Surveillance colonoscopy with chromoendoscopy starts approximately eight years after symptom onset; interval one to five years based on risk. Primary sclerosing cholangitis (PSC) combined with IBD warrants annual surveillance from diagnosis — the highest-risk IBD combination.

Post-CRC surveillance — after curative resection, colonoscopy at one year, then three years, then five-yearly per consensus. CT of the chest, abdomen, and pelvis for staging recurrence is separate from colonoscopy surveillance and follows oncology protocols.

When to escalate

Refer urgently within days for:

• Suspected colorectal cancer — definite rectal mass, obstructive symptoms, iron deficiency anaemia with significant bleeding or falling haemoglobin — gastroenterology or colorectal surgery urgent access
• Positive iFOBT in a patient who is symptomatic — doubly urgent: they need diagnostic colonoscopy, not just surveillance

Refer within weeks for:

• Positive iFOBT in an asymptomatic patient — target colonoscopy within 30 days
• Family history placing patient in category 2 or 3 — colonoscopy surveillance commencement, or genetic assessment
• Suspected Lynch syndrome or FAP — Familial Cancer Centre referral

What this article is and is not

This is general health information drawn from the NBCSP, Cancer Council Australia surveillance guidelines, NHMRC guidelines, eTG, RACGP Red Book, and GESA. It is not personal medical advice. Individual surveillance intervals and investigation timing are determined with your own GP and specialist.

For Australian consumer resources: Bowel Cancer Australia 1800 555 494, HealthDirect — Bowel cancer screening, Better Health Channel, Cancer Council 13 11 20.

---

Sources cited

1. NBCSP
2. Cancer Council Australia — Surveillance Colonoscopy Guidelines
3. NHMRC — Colorectal Cancer Guidelines
4. RACGP Red Book
5. GESA
6. eTG
7. Bowel Cancer Australia
8. Cochrane — FOBT screening for CRC (Hewitson)
9. USPSTF 2021 — Colorectal cancer screening (age 45–75)
10. HealthDirect — Bowel cancer screening
11. Better Health Channel